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Objective. To assess cumulative survival rates and identify independent predictors of mortality in patients with incident
systemic sclerosis (SSc)–associated pulmonary arterial hypertension (PAH) who had undergone routine screening for
PAH at SSc centers in the US.
Methods. The Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma registry is a prospec-
tive registry of SSc patients at high risk for PAH or with deﬁnite pulmonary hypertension diagnosed by right-sided heart
catheterization within 6 months of enrollment. Only patients with World Health Organization group I PAH (mean
pulmonary artery pressure >25 mm Hg and pulmonary capillary wedge pressure <15 mm Hg without signiﬁcant
interstitial lung disease) were included in these analyses.
Results. In total, 131 SSc patients with incident PAH were followed for a mean  SD of 2.0  1.4 years. The 1-, 2-, and
3-year cumulative survival rates were 93%, 88%, and 75%, respectively. On multivariate analysis, age >60 years (hazard
ratio [HR] 3.0, 95% conﬁdence interval [95% CI] 1.1–8.4), male sex (HR 3.9, 95% CI 1.1–13.9), functional class (FC) IV
status (HR 6.5, 95% CI 1.8–22.8), and diffusing capacity for carbon monoxide (DLCO) <39% predicted (HR 4.2, 95% CI
1.3–13.8) were signiﬁcant predictors of mortality.
Conclusion. This is the largest study describing survival in patients with incident SSc-associated PAH followed up at
multiple SSc centers in the US who had undergone routine screening for PAH. The survival rates were better than those
reported in other recently described SSc-associated PAH cohorts. Severely reduced DLCO and FC IV status at the time of
PAH diagnosis portended a poor prognosis in these patients.
Introduction
Pulmonary arterial hypertension (PAH) as conﬁrmed by
right-sided heart catheterization (RHC) affects 8–12% of
patients with systemic sclerosis (SSc; scleroderma) (1,2)
and is associated with a 3-fold increased risk of death
compared with SSc patients without PAH (3,4). Compared
to patients with idiopathic PAH and other forms of con-
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nective tissue disease (CTD)–associated PAH (5), patients
with SSc-associated PAH experience poorer outcomes. De-
spite the availability of several PAH-speciﬁc therapies,
recent studies of patients with incident SSc-associated
PAH have estimated 1- and 3-year survival rates ranging
from 72–86% and 39–67%, respectively (1,3,6–8). Be-
cause several studies have indicated that early treatment of
PAH can improve hemodynamics, exercise capacity, and
survival (9–11), guidelines for the screening and early
detection of PAH in SSc patients who are at high risk for
PAH have been developed (12). The Pulmonary Hyperten-
sion Assessment and Recognition of Outcomes in Sclero-
derma (PHAROS) registry was established in 2006 to as-
sess the outcomes of patients at high risk for developing
PAH and of those with incident disease. The premise of
the PHAROS registry is that early detection and close
monitoring of PAH in SSc patients could improve health-
related outcomes. Herein, we describe the cumulative sur-
vival rates and predictors of mortality in this cohort of
patients with SSc-associated PAH followed up at special-
ized scleroderma centers throughout the US.
Patients and methods
The PHAROS registry is a longitudinal prospective regis-
try involving 22 US scleroderma centers. The participating
centers obtained institutional review board approval and
all patients provided written informed consent prior to
enrollment. The baseline characteristics and study design
for the PHAROS registry have been described elsewhere
(13).
The PHAROS registry enrolled SSc patients who were at
high risk for developing pulmonary hypertension (PH; pre-
PH) or who had deﬁnite PH diagnosed by RHC within 6
months of enrollment. Pre-PH patients must have fulﬁlled
one of the following 3 criteria: 1) right ventricular systolic
pressure (RVSP) on transthoracic echocardiogram (TTE)
40 mm Hg (calculated as the pressure gradient between
the right ventricle and right atrium using the maximum
velocity of the tricuspid regurgitant jet plus the right
atrium pressure), 2) forced vital capacity (FVC) 70%
predicted and diffusing capacity for carbon monoxide
(DLCO) 55% predicted, or 3) %FVC:%DLCO ratio 1.6.
All SSc patients at all centers were to undergo at least
annual TTE and pulmonary function tests (PFTs) to screen
for PAH at the time of registry enrollment. RHC was ob-
tained in pre-PH patients as clinically indicated and de-
termined by the treating physician. Patients with deﬁnite
PH must have had a mean pulmonary artery pressure
(PAP) 25 mm Hg at rest on RHC performed within the 6
months prior to enrollment into the registry. Only patients
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Signiﬁcance & Innovations
● The 1-, 2-, and 3-year cumulative survival rates
were 93%, 88%, and 75%, respectively, in this
multicenter US cohort of patients with incident
systemic sclerosis (SSc)–associated pulmonary ar-
terial hypertension (PAH) who had undergone
routine screening for PAH.
● Severely decreased diffusing capacity for carbon
monoxide and functional class IV status at the
time of the PAH diagnosis portended a poor prog-
nosis in SSc patients, particularly in older patients
and in men.
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cording to the 2009 Dana Point Classiﬁcation Criteria for
PH, with a mean PAP 25 mm Hg and pulmonary capil-
lary wedge pressure 15 mm Hg on RHC without signiﬁ-
cant interstitial lung disease deﬁned as an FVC 65%
predicted and no or only mild ﬁbrosis on a high-resolution
computed tomography (HRCT) scan of the chest, were
included in this analysis. The pre-PH patients could be
recategorized as having deﬁnite PH based on RHC over the
course of the study, and these patients were included in
this analysis.
A subgroup analysis of patients who received 3 con-
tinuous months of the same PAH-speciﬁc therapies over
the ﬁrst year of followup was performed. For this subgroup
analysis, patients were divided into 4 different treatment
categories based on the following initial PAH-speciﬁc
therapy used as determined by the treating physicians:
1) endothelin receptor antagonist (ERA) monotherapy,
2) phosphodiesterase 5 (PDE-5) inhibitor monotherapy,
3) prostacyclin analogue (PCA) monotherapy, or 4) com-
bination therapy with at least 2 PAH-speciﬁc therapeutic
classes.
The following information was collected at baseline and
on annual followup: demographics, medications, physical
examination ﬁndings, New York Heart Association (NYHA)
functional class (FC) assessment, serum autoantibodies,
brain natriuretic peptide (BNP)/N-terminal proBNP levels
if available, PFT results, TTE results, ﬁndings on HRCT,
6-minute walk distance (6MWD), and hemodynamics on
RHC if performed. The primary outcome measure was
death and the causes of death were recorded if known.
For statistical analysis, baseline characteristics were as-
sessed by descriptive statistics. Kaplan-Meier curves were
estimated for survival from the time of the ﬁrst RHC at
which PAH was conﬁrmed. The differences in outcomes
between subgroups were assessed by the log rank test. Cox
regression models were used to identify signiﬁcant predic-
tors of mortality. DLCO, mean PAP, and pulmonary vascu-
lar resistance (PVR) were evaluated as categorical variables
using the median value as the cut point. Demographic
variables and those with a P value less than 0.1 in the
univariate analyses were included in a multivariate model.
Backward selection was used to determine the ﬁnal model,
retaining only variables with a P value less than 0.05.
For the analysis evaluating the effect of PAH-speciﬁc
therapies on outcomes, Kaplan-Meier curves were esti-
mated for 1-year survival from the time PAH-speciﬁc med-
ication(s) were started, with differences between the treat-
ment categories assessed by the log rank test.
Results
Baseline characteristics. Of the 434 patients enrolled in
the PHAROS registry at the time of this analysis, 131 had
incident PAH as determined by RHC during the study, 14
of whom developed RHC-proven PAH after enrollment
into the registry (Table 1). At the PAH diagnosis, the
mean  SD age was 60.4  10.4 years and the mean  SD
disease duration from the ﬁrst Raynaud’s phenomenon
and ﬁrst non–Raynaud’s phenomenon symptoms was
14.4  12.0 and 10.3  9.2 years, respectively. The major-
ity of patients were women (84%), were white (82%), and
had limited cutaneous disease (70%). Approximately one-
third of the patients were anticentromere antibody posi-
tive, 7% were Scl-70 positive, 6% had an anti–U1 RNP
antibody, 4% were RNA polymerase III positive, 24% had
an antinuclear antibody (ANA) with an isolated nucleolar
pattern without other scleroderma-speciﬁc antibodies,
22% had a positive ANA alone without a nucleolar pattern
Table 1. Baseline characteristics of patients with
systemic sclerosis–associated pulmonary arterial
hypertension in the PHAROS registry*
Clinical feature (no. of patients) Value
Age, mean  SD years (131) 60.4  10.4
Women, no. (%) (131) 110 (84)
Race, no. (%) (131)
White 108 (82)
African American 13 (10)
Other 10 (8)
Limited cutaneous systemic sclerosis,
no. (%) (130)
92 (70)
Time from ﬁrst Raynaud’s phenomenon
symptom, mean  SD years (131)
14.4  12.0
Time from ﬁrst non–Raynaud’s
phenomenon symptom, mean  SD
years (131)
10.3  9.2
Autoantibodies, no. (%) (123)
Anticentromere antibodies 44 (35.8)
Anti–Scl-70 antibodies 9 (7.3)
Anti–RNA polymerase III antibodies 5 (4.1)
Anti–U1 RNP antibodies 7 (5.7)
Nucleolar pattern of ANAs 30 (24.4)
Positive ANAs alone 27 (22.0)
Negative 6 (4.9)
Creatinine, mean  SD mg/dl (131) 1.0  0.6
New York Heart Association functional
class, no. (%) (128)
I 24 (18.8)
II 48 (37.5)
III 49 (38.3)
IV 7 (5.5)
6-minute walk distance, mean  SD
meters (101)
339  130
Pulmonary function tests, mean  SD
FVC% predicted (121) 82  16
DLCO% predicted (116) 42  16
FVC%:DLCO% ratio (116) 2.2  0.9
Transthoracic echocardiogram
Right ventricular systolic pressure,
mean  SD mm Hg (117)
61  20
Pericardial effusion, no. (%) (111) 44 (39.6)
Right-sided heart catheterization,
mean  SD
Mean pulmonary artery pressure,
mm Hg (131)
36.5  10.3
Pulmonary vascular resistance,
WUs (123)
5.6  3.4
Pulmonary capillary wedge pressure,
mm Hg (131)
10.1  3.3
Cardiac output, liters/minute (131) 5.0  1.5
* PHAROS  Pulmonary Hypertension Assessment and Recogni-
tion of Outcomes in Scleroderma; ANAs  antinuclear antibodies;
FVC  forced vital capacity; DLCO  diffusing capacity for carbon
monoxide; WUs  Wood units.
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or other scleroderma-speciﬁc antibodies, and 5% were
negative for all autoantibodies. Only 2.3% of patients had
a creatinine level 2 mg/dl at the time of RHC, and the
median creatinine level was 0.9 mg/dl.
Figure 1. Survival in patients with systemic sclerosis (SSc)–associated pulmonary arterial hyper-
tension (PAH) in the Pulmonary Hypertension Assessment and Recognition of Outcomes in
Scleroderma registry. The 1-, 2-, and 3-year survival rates in the 131 patients with SSc-associated
PAH were 93%, 88%, and 75%, respectively (A). New York Heart Association functional class (FC)
IV status (B) and diffusing capacity for carbon monoxide (DLCO) 38.9% predicted (C) were
associated with poorer survival.
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More than half of the patients were classiﬁed as having
NYHA FC I (18%) or II (37%) status at the time of RHC,
while only 5% of the patients were classiﬁed as having FC
IV status. The mean  SD RVSP on TTE was 61  20 mm
Hg, and 39.6% of the patients had a pericardial effusion.
On baseline pulmonary evaluation, the mean  SD DLCO
was 42% 16% predicted and the mean SD 6MWDwas
339  130 meters. Half of the patients had a baseline DLCO
40% predicted, while only 11% of the patients had se-
verely compromised exercise capacity, deﬁned as a 6MWD
165 meters. The baseline hemodynamics were relatively
mild, with a mean  SD PAP of 36.5  10.3 mm Hg
(median 35), mean  SD PVR of 5.6  3.4 Wood units
(WUs; median 4.6), and mean SD cardiac output of 5.0
1.5 liters/minute.
Survival. In total, 24 patients (18%) died over a mean
SD followup time of 2.0  1.4 years (median 2.0 years
[range 0–5.9 years]); 20 deaths (83%) were directly attrib-
utable to PAH or multiorgan failure related to underlying
PAH. Other causes of death included new-onset sclero-
derma renal crisis (2 patients), infection (1 patient), and
cancer (1 patient). The 1-, 2-, and 3-year survival rates in
the overall SSc-associated PAH cohort were 93%, 88%,
and 75%, respectively (Figure 1A).
Predictors of mortality. The univariate regression ana-
lysis identiﬁed FC IV status (hazard ratio [HR] 6.0, 95%
conﬁdence interval [95% CI] 2.0–18.2), DLCO 39% pre-
dicted (HR 4.3, 95% CI 1.6–11.9), and PVR 4.6 WUs (HR
3.4, 95% CI 1.3–8.7) as signiﬁcant predictors of mortality
(Table 2 and Figures 1B and C). On multivariate analysis,
FC IV status (HR 6.5, 95% CI 1.8–22.8) and DLCO 39%
predicted (HR 4.2, 95% CI 1.3–13.8) remained signiﬁcant,
while age60 years (HR 3.0, 95% CI 1.1–8.4) and male sex
(HR 3.9, 95% CI 1.1–13.9) were also independent predic-
tors of mortality.
Effect of PAH-speciﬁc therapies on survival. Of the
overall SSc-associated PAH cohort, 101 patients had re-
ceived 3 continuous months of their initial PAH-speciﬁc
therapies and 1 year of followup. The initial PAH treat-
ment categories were as follows: ERA in 30%, PDE-5 in
48%, PCA in 13% (85% inhaled and 15% parenteral), and
combination therapy in 10% of patients. Patients in the
PCA group had a signiﬁcantly lower mean  SD DLCO at
29% 11% predicted compared with 45% 18%, 42%
14%, and 35%  11% in the PDE-5, ERA, and combina-
tion therapy groups (P 0.03), respectively. Patients in the
PCA group also had worse hemodynamics at the time of
PH therapy initiation. The PCA group had a higher median
mean PAP of 45 mm Hg (interquartile range [IQR] 40–45)
compared with 35 mmHg (IQR 29–40) in the PDE-5 group,
30 mm Hg (IQR 27–38) in the ERA group, and 38 mm Hg
(IQR 33–53) in the combination therapy group (P 
0.0008). PCA patients also had a signiﬁcantly higher
mean  SD PVR of 7.0  2.8 WUs, compared with 4.8 
2.7 WUs for PDE-5, 3.7  2.1 WUs for ERA, and 6.9  2.1
WUs for combination therapy patients (P  0.0004). The
prostacyclin-treated patients clearly had worse hemody-
namics, suggesting a sicker population. At 1 year, 7 pa-
tients (7%) who were receiving PAH-speciﬁc therapies
died. The 1-year survival rate was signiﬁcantly worse in
the PCA group (69%) compared with the other treatment
categories (ERA 97%, PDE-5 98%, and combination ther-
apy 90%; P  0.002).
Discussion
Our study described the outcomes of a large US SSc-
associated PAH cohort of incident patients who had close
Table 2. Predictors of mortality using univariate and multivariate Cox regression analyses*
Hazard ratio
(95% CI) P
Univariate (no. of patients)
Age 60 years (131) 1.7 (0.7–3.8) 0.22
Male sex (131) 2.3 (0.9–6.4) 0.09
Nonwhite (131) 1.1 (0.4–3.0) 0.8
NYHA FC IV (128) 6.0 (2.0–18.2) 0.002
6MWD 165 meters (101) 2.5 (0.9–6.9) 0.09
Pericardial effusion (111) 1.1 (0.5–2.6) 0.9
DLCO 39% predicted (116) 4.3 (1.6–11.9) 0.005
Anticentromere antibody positive (123) 1.2 (0.5–2.9) 0.7
Mean PAP 35 mm Hg (117) 1.6 (0.7–3.6) 0.28
PVR 4.6 WUs (124) 3.4 (1.3–8.7) 0.01
Creatinine 0.9 mg/dl (124) 1.9 (0.8–4.5) 0.17
Multivariate (n  85)
Age 60 years 3.0 (1.1–8.4) 0.04
Male sex 3.9 (1.1–13.9) 0.03
NYHA FC IV 6.5 (1.8–22.8) 0.004
DLCO 39% predicted 4.2 (1.3–13.8) 0.02
* 95% CI  95% conﬁdence interval; NYHA FC IV  New York Heart Association functional class IV; 6MWD 
6-minute walk distance; DLCO  diffusing capacity for carbon monoxide; PAP  pulmonary artery pressure;
PVR  pulmonary vascular resistance; WUs  Wood units.
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longitudinal followup at centers with a special interest in
SSc. We found improved survival rates of 93% and 75% at
1 and 3 years, respectively, compared with other recently
described SSc cohorts, including the US Registry to Eval-
uate Early and Long Term PAH Disease Management
(REVEAL), which reported rates of 78% and 54% at 1 and
3 years, respectively (1,3,6–8). We recognize that a direct
comparison of survival rates between the PHAROS registry
and other cohorts is not possible; however, our cohort was
enriched in patients with less severe disease (56% of
patients with FC I and II status versus 23% in REVEAL),
which was likely due to screening and early detection
of PAH. In total, 17% of deaths were unrelated to PAH,
highlighting that other comorbid conditions inﬂuenced
outcome in SSc-associated PAH patients.
Our results concur with other smaller studies following
early detection algorithms. Hachulla et al found 1- and
3-year survival rates of 100% and 80%, respectively, in 12
patients with SSc-associated PAH who were classiﬁed as
having NYHA FC II status at diagnosis (10). Similarly,
Humbert et al compared survival rates in 16 patients with
SSc-associated PAH diagnosed in routine practice with 16
patients diagnosed following a systematic PAH detection
program, with 1-, 3-, 5-, and 8-year survival rates of 75%,
31%, 25%, and 17%, respectively, in the former group
compared with 100%, 81%, 73%, and 64%, respectively,
in the early detection group (11). A recent Australian study
of 117 patients with CTD-associated PAH had 1- and
3-year survival rates similar to ours (94% and 73%, respec-
tively) (14). Although the latter cohort primarily com-
prised patients with SSc-associated PAH, better outcomes
were observed in non-SSc patients with CTD-associated
PAH (5,8), which may have skewed the results.
On multivariate analysis, we found that older age, male
sex, NYHA FC IV status, and low DLCO were independent
predictors of mortality. Similarly, Condliffe et al found
that younger age, female sex, and a lower NYHA FC were
protective in patients with SSc-associated PAH (8). A
DLCO 39% predicted at PAH diagnosis was associated
with a 4-fold increased risk of death in our cohort. Chan-
dra et al found that a DLCO43% predicted was associated
with a lower HR of 2.4 (95% CI 1.1–5.0) in a cohort of 408
patients with WHO group I PAH, including 142 patients
with CTD-associated PAH, but the number of SSc-associ-
ated PAH patients was not reported (15). Our results em-
phasize the importance of monitoring DLCO for both PAH
screening and prognostic purposes in patients with SSc.
Unlike other PAH studies, we did not ﬁnd an increased
risk of death associated with the presence of a pericardial
effusion, NYHA FC III status, or low 6MWD, which may
reﬂect the effect of multisystem disease manifestations in
SSc on these variables.
The patients started on PCA as initial therapy had the
poorest survival of all treatment groups, but this was likely
confounded by more severe disease at baseline. Given the
short length of followup, it is difﬁcult to make deﬁnitive
conclusions regarding treatment outcomes, and additional
followup data are being collected.
We recognize that there are limitations to this study.
Although our study was a prospective multicenter cohort,
it was observational and therefore missing data were inev-
itable, particularly data on BNP/N-terminal proBNP levels.
We also did not collect information on mean right atrial
pressure, an important predictor of mortality in other SSc-
associated PAH studies (1,14). Lead-time bias may have
contributed to the improved survival rates observed in this
population of patients with SSc-associated PAH who were
diagnosed earlier with less severe disease due to existing
PAH screening programs. Finally, PAH therapies were de-
termined by the individual treating physicians, and not in
a randomized controlled fashion.
Our study provided further evidence that early detection
and management of PAH in SSc patients may lead to
improved outcomes. Severely decreased DLCO and FC IV
status at the time of PAH diagnosis portend a poor prog-
nosis in SSc patients, particularly in older patients and
men.
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